DIVISLAB2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member DIVISLAB2021-04-012021-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2021-04-01 2022-03-31 2021-07-30 INR Lakhs First quarter Single segment Pharmaceuticals 2021-04-01 2021-06-30 Unaudited Standalone 19501600000.00 355500000.00 19857100000.00 7637500000.00 0.00 -1195300000.00 2162600000.00 2400000.00 730100000.00 2382100000.00 11719400000.00 8137700000.00 0.00 8137700000.00 2394800000.00 223200000.00 2618000000.00 0.00 5519700000.00 0.00 0.00 0.00 0.00 5519700000.00 400000.00 5520100000.00 0.00 0.00 530900000.00 2 20.79 20.79 0.00 0.00 20.79 20.79 1. The above Statement of Standalone Unaudited Financial Results for the quarter ended 30th June, 2021 (“Statement’) is prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 7th August,2021. The Statement is subjected to ‘limited review’ by the Auditors of the Company and their report contains no qualification. 2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients; and the same constitutes a single reporting business segment as per Ind AS108. 3. The Company does not have any discontinued operations and the profit for the period represents profits from continuing operations only. 4. The Company has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Company will continue to closely monitor for any material changes to future economic conditions. 5. Forex gain included in Other Income and loss included in Other Expenses for the respective periods is as given below: Rs. in lakhs Quarter Ended Year Ended 30.06.2021 31.03.2021 30.06.2020 31.03.2021 Forex gain /(loss) 1922 327 535 (77) 6. *Figures for the quarter ended 31.03.2021 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year. Other Expenses 2382100000.00